Akebia Therapeutics (AKBA) Tops Q1 EPS by 8c

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $57.34 million versus the consensus estimate of $44.38 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Magnolia Said In Lead To Acquire Wildfire For Over $4 Billion - Bloomberg
• Goldman Sachs Reiterates Buy Rating on NetEase.com (NTES)